We report on the extremely rare finding of a multiple synchronous, partly free perforated carcinoma of the small bowel. The histopathological diagnosis was a small-cell carcinoma of the small bowel. Malignant lymphoma, neuroendocrine or neuroendothelial malignancies were excluded immunohistochemically. In light of the intraoperative finding and the postoperative diagnostics, we are of the opinion that it is a primary multiple synchronous carcinoma of the small bowel.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00571688 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objectives: The pairing of immunotherapy and radiotherapy in the treatment of locally advanced nonsmall cell lung cancer (NSCLC) has shown promise. By combining radiotherapy with immunotherapy, the synergistic effects of these modalities not only bolster antitumor efficacy but also exacerbate lung injury. Consequently, developing a model capable of accurately predicting radiotherapy- and immunotherapy-related pneumonitis in lung cancer patients is a pressing need.
View Article and Find Full Text PDFCancer is a condition in which cells in the body grow uncontrollably, often forming tumours and potentially spreading to various areas of the body. Cancer is a hazardous medical case in medical history analysis. Every year, many people die of cancer at an early stage.
View Article and Find Full Text PDFSpectrum of gastric neoplasms in Helicobacter pylori-naïve patients.
Dig Endosc
January 2025
Department of Gastroenterology, Faculty of Medicine, Shimane University, Shimane, Japan.
Chronic Helicobacter pylori (Hp) infection is the largest etiological factor for gastric cancer, but in recent years the reports of Hp-naïve gastric neoplasms (HpNGNs) have increased as the Hp-infected population in Japan has been declining. The histopathologic spectrum of HpNGNs differs significantly from that of conventional Hp-infected gastric neoplasms. Molecularly, the former harbor considerably fewer genetic and epigenetic abnormalities, reflecting the absence of chronic inflammatory conditions in the gastric mucosa.
View Article and Find Full Text PDFReal-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations.
BMC Cancer
January 2025
Department of Urology, Yamagata University School of Medicine, Iida-Nishi 2-2-2, Yamagata, 990-9585, Japan.
Background: Immune-combinations have recently become the standard first-line treatment for patients with metastatic renal cell carcinoma (mRCC). This study evaluated the applicability of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model in predicting outcomes for patients treated with either immune-oncologic drug doublet (IO-IO) or immune-oncologic drug tyrosine kinase inhibitor combinations (IO-TKI). A secondary objective to compare the effectiveness of IO-IO versus IO-TKI within the IMDC risk groups over a short follow-up period.
View Article and Find Full Text PDFSurgery versus concurrent chemoradiotherapy for stage III non-small cell lung cancer: a retrospective study with propensity score matching.
BMC Cancer
January 2025
Department of Thoracic Surgery, Yokohama Municipal Citizen's Hospital, 1-1, Mitsuzawanishimachi, Kanagawa-ku, Yokohama City, Kanagawa Prefecture, 221-0855, Japan.
Background: No study has directly compared the outcomes of surgery and concurrent chemoradiotherapy (cCRT) in patients with stage III non-small cell lung cancer (NSCLC) to date. This study aimed to compare the treatment efficacy of complete resection and definitive cCRT.
Methods: Patients were recruited in this retrospective study from Yokohama Municipal Citizens' Hospital between January 2013 and December 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!